Concerning the relationships between genes, risk factors and immunity in Alzheimer's disease, Autism, Bipolar disorder , multiple sclerosis, Parkinson's disease, schizophrenia and chronic fatigue
Evaluating the first drug to show improvement in subtype of autism
In an important test of one of the first drugs to target core symptoms of autism, researchers at Mount Sinai School of Medicine are undertaking a pilot clinical trial to evaluate insulin-like growth factor (IGF-1) in children who have SHANK3 deficiency (also known as 22q13 Deletion Syndrome or Phelan-McDermid Syndrome), a known cause of autism spectrum disorder (ASD).
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment